{"ATC Code":"M - Musculo-skeletal system","Abbreviation":"","Aliases":["4-Butyl-1,2-diphenylpyrazolidine-3,5-dione","Butapirazol","Butazolidin","Fenilbutazona","Butadion","Diphenylbutazone","Butazolidine","Fenibutazona","Fenylbutazon","Intrabutazone"],"Biological Half-Life":"Biological half-life of phenylbutazone in plasma was about 6 hr in dogs, 5 hr in guinea-pigs and 3 hr in rabbits.","CAS":"50-33-9","ChEBI":"CHEBI:48574","ChemicalClasses":[],"Chirality":"achiral","Classes":null,"Color/Form":"Crystals from ethanol","Decomposition":"When heated to decomposition it emits toxic fumes of /nitrogen oxides/.","Dosing Info":[],"Drug Indication":"For the treatment of backache and ankylosing spondylitis","Drug Warnings":"Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man. To guard against this possibility, conduct routine blood counts at weekly intervals of two weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.","DrugClasses":[],"EINECS":"200-029-0","EliminationHalfLife":"","European Community (EC) Number":"200-029-0","HMDB ID":"HMDB0014950","HeavyAtomCount":23,"Human Drugs":"Human drug -\u003e Discontinued; Active ingredient (PHENYLBUTAZONE)","IUPACName":"4-butyl-1,2-diphenylpyrazolidine-3,5-dione","Impurities":["benzidine","azobenzene","bumadizone","1,2-diphenylhydrazine","4-hydroxyphenylbutazone"],"InChI":"InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3","InChIKey":"VYMDGNCVAMGZFE-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)","Melting Point":"219 to 225 °F (NTP, 1992)","MolecularFormula":"C\u003csub\u003e19\u003c/sub\u003eH\u003csub\u003e20\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"308.4 g/mol","Odor":"ODORLESS","Pharmacodynamics":"Phenylbutazone is a synthetic, pyrazolone derivative. It is a nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties and arise from its ability to reduce production of prostaglandin H and prostacyclin. Prostaglandins act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostacylcin causes vascular constriction platelet disaggregation","Physical Description":"Phenylbutazone appears as odorless white or off-white crystalline powder. Tasteless at first, but slightly bitter aftertaste. pH (aqueous solution) 8.2. (NTP, 1992)","PrevSalts":[],"PubChemId":4781,"Record Description":["Phenylbutazone appears as odorless white or off-white crystalline powder. Tasteless at first, but slightly bitter aftertaste. pH (aqueous solution) 8.2. (NTP, 1992)","Phenylbutazone is a member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position. It has a role as a non-narcotic analgesic, a non-steroidal anti-inflammatory drug, an antirheumatic drug, a peripheral nervous system drug, a metabolite and an EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor.","A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)","Phenylbutazone has been reported in Euglena gracilis with data available.","PHENYLBUTAZONE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved indications. It was withdrawn in at least one region.","A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.","Phenylbutazone is a member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position. It has a role as a non-narcotic analgesic, a non-steroidal anti-inflammatory drug, an antirheumatic drug, a peripheral nervous system drug, a metabolite and an EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor."],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Phenylbutazone","Name":"Phenylbutazone","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q421342","Name":"Phenylbutazone","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00812","Name":"Phenylbutazone","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4781","Name":"Phenylbutazone","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:48574","Name":"Phenylbutazone","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=50-33-9","Name":"Phenylbutazone","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014950","Name":"Phenylbutazone","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D00510","Name":"Phenylbutazone","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/GN5P7K3T8S","Name":"Phenylbutazone","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9021136","Name":"Phenylbutazone","Sub":false}]}],"SMILES":"CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3","Scheduling":[],"Solubility":"\u003e46.3 [ug/mL] (The mean of the results at pH 7.4)","StoreUNII":["GN5P7K3T8S"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="94.328mm" version="1.2" viewBox="0 0 113.668 94.328" width="113.668mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="95.0" stroke="none" width="114.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="112.724" x2="97.568" y1="2.649" y2="1.049"/>
                  
            <line class="bond" id="mol1bnd2" x1="97.568" x2="88.604" y1="1.049" y2="13.374"/>
                  
            <line class="bond" id="mol1bnd3" x1="88.604" x2="73.449" y1="13.374" y2="11.775"/>
                  
            <line class="bond" id="mol1bnd4" x1="73.449" x2="64.485" y1="11.775" y2="24.1"/>
                  
            <line class="bond" id="mol1bnd5" x1="64.485" x2="69.159" y1="24.1" y2="38.527"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line x1="68.696" x2="80.447" y1="37.097" y2="40.883"/>
                        
                <line x1="67.948" x2="79.699" y1="39.418" y2="43.204"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="80.447" x2="74.5715" y1="40.883" y2="38.99"/>
                <line class="hi" stroke="#FF0D0D" x1="79.699" x2="73.8235" y1="43.204" y2="41.311"/>
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="69.159" x2="59.934" y1="38.527" y2="45.313"/>
                  
            <line class="bond" id="mol1bnd8" x1="53.797" x2="47.64" y1="45.313" y2="40.784"/>
                  
            <line class="bond" id="mol1bnd9" x1="45.797" x2="49.245" y1="34.746" y2="24.1"/>
                  
            <line class="bond" id="mol1bnd10" x1="64.485" x2="49.245" y1="24.1" y2="24.1"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="48.781" x2="41.611" y1="25.534" y2="15.676"/>
                        
                <line x1="50.753" x2="43.583" y1="24.1" y2="14.241"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="41.611" x2="45.196" y1="15.676" y2="20.605"/>
                <line class="hi" stroke="#FF0D0D" x1="43.583" x2="47.168" y1="14.241" y2="19.1705"/>
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="41.298" x2="30.066" y1="39.582" y2="43.201"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="30.066" x2="18.763" y1="43.201" y2="32.966"/>
                        
                <line x1="27.387" x2="18.17" y1="44.064" y2="35.718"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="18.763" x2="4.257" y1="32.966" y2="37.639"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="4.257" x2="1.054" y1="37.639" y2="52.547"/>
                        
                <line x1="6.345" x2="3.734" y1="39.528" y2="51.684"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="1.054" x2="12.358" y1="52.547" y2="62.782"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="12.358" x2="26.863" y1="62.782" y2="58.109"/>
                        
                <line x1="12.95" x2="24.775" y1="60.03" y2="56.22"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="30.066" x2="26.863" y1="43.201" y2="58.109"/>
                  
            <line class="bond" id="mol1bnd19" x1="56.865" x2="56.865" y1="51.42" y2="62.81"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="56.865" x2="43.657" y1="62.81" y2="70.43"/>
                        
                <line x1="56.865" x2="46.096" y1="65.625" y2="71.838"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="43.657" x2="43.657" y1="70.43" y2="85.67"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="43.657" x2="56.865" y1="85.67" y2="93.29"/>
                        
                <line x1="46.096" x2="56.865" y1="84.261" y2="90.475"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="56.865" x2="70.073" y1="93.29" y2="85.67"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="70.073" x2="70.073" y1="85.67" y2="70.43"/>
                        
                <line x1="67.635" x2="67.635" y1="84.261" y2="71.838"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="56.865" x2="70.073" y1="62.81" y2="70.43"/>
                  
            <path class="atom" d="M85.924 43.198q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM82.06 43.198q.0 .922 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.536 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" id="mol1atm7" stroke="none"/>
                  
            <path class="atom" d="M58.806 50.02h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.023 -.477q-.006 -.261 -.006 -.482v-2.768h.577v4.9z" fill="#3050F8" id="mol1atm8" stroke="none"/>
                  
            <path class="atom" d="M46.512 40.977h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm9" stroke="none"/>
                  
            <path class="atom" d="M42.541 11.772q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM38.678 11.772q-.0 .922 .387 1.458q.393 .53 1.22 .53q.839 .0 1.22 -.53q.387 -.536 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm11" stroke="none"/>
                
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="59.934" x2="64.54650000000001" y1="45.313" y2="41.92"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="53.797" x2="50.7185" y1="45.313" y2="43.048500000000004"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="47.64" x2="50.7185" y1="40.784" y2="43.048500000000004"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="45.797" x2="47.521" y1="34.746" y2="29.423000000000002"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="41.298" x2="35.682" y1="39.582" y2="41.3915"/>
            <line class="hi" id="mol1bnd19" stroke="#3050F8" x1="56.865" x2="56.865" y1="51.42" y2="57.115"/>
        </g>
          
    </g>
    
</svg>
","Taste":"Slightly bitter taste","Therapeutic Uses":"Anti-Inflammatory Agents, Non-Steroidal","Title":"Phenylbutazone","UNII":"GN5P7K3T8S","Wikidata":"Q421342","Wikipedia":"Phenylbutazone","XLogP":3.2,"pH":"pH of aqueous solution = 8.2"}